WO2004085642A1 - 関節炎関連遺伝子及びこれの関節炎検査等への利用 - Google Patents

関節炎関連遺伝子及びこれの関節炎検査等への利用 Download PDF

Info

Publication number
WO2004085642A1
WO2004085642A1 PCT/JP2004/004352 JP2004004352W WO2004085642A1 WO 2004085642 A1 WO2004085642 A1 WO 2004085642A1 JP 2004004352 W JP2004004352 W JP 2004004352W WO 2004085642 A1 WO2004085642 A1 WO 2004085642A1
Authority
WO
WIPO (PCT)
Prior art keywords
arthritis
midkine
remedy
onset
examining
Prior art date
Application number
PCT/JP2004/004352
Other languages
English (en)
French (fr)
Inventor
Takashi Muramatsu
Kiyoko Maruyama
Hisako Muramatsu
Naoki Ishiguro
Original Assignee
Takashi Muramatsu
Kiyoko Maruyama
Hisako Muramatsu
Naoki Ishiguro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Muramatsu, Kiyoko Maruyama, Hisako Muramatsu, Naoki Ishiguro filed Critical Takashi Muramatsu
Priority to JP2005504126A priority Critical patent/JP4646070B2/ja
Publication of WO2004085642A1 publication Critical patent/WO2004085642A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

本発明は、関節炎、特にリウマチ性関節炎の発症に関与する因子の解明を第一の目的とし、さらに、見出した因子をターゲットとした関節炎治療薬のスクリーニング方法、関節炎治療薬ならびに検査薬を提供することを課題とする。　ミッドカイン遺伝子ノックアウトマウスでは関節炎の発症が野性型マウスに比較して有意に少なかった。また、関節リウマチ患者のほとんどの例では血清中および滑膜液中のミッドカインレベルが高値であった。このことからミッドカイン発現と関節リウマチとの間に強い相関があることが示された。ミッドカイン遺伝子欠損マウスへのミッドカインの投与により、抗体誘導性関節炎の頻度が高まった。
PCT/JP2004/004352 2003-03-27 2004-03-26 関節炎関連遺伝子及びこれの関節炎検査等への利用 WO2004085642A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005504126A JP4646070B2 (ja) 2003-03-27 2004-03-26 関節炎関連遺伝子及びこれの関節炎検査等への利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003127573 2003-03-27
JP2003-127573 2003-03-27

Publications (1)

Publication Number Publication Date
WO2004085642A1 true WO2004085642A1 (ja) 2004-10-07

Family

ID=33095351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004352 WO2004085642A1 (ja) 2003-03-27 2004-03-26 関節炎関連遺伝子及びこれの関節炎検査等への利用

Country Status (2)

Country Link
JP (1) JP4646070B2 (ja)
WO (1) WO2004085642A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055378A1 (ja) * 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
WO2008059877A1 (fr) 2006-11-14 2008-05-22 Ribomic Inc. Aptamère contre la midkine et son utilisation
WO2008059616A1 (fr) 2006-11-14 2008-05-22 Medical Therapies Limited Anticorps reconnaissant le domaine c de la midkine
WO2014021339A1 (ja) 2012-07-30 2014-02-06 国立大学法人名古屋大学 ヒトミッドカインに対するモノクローナル抗体
WO2020022499A1 (ja) * 2018-07-27 2020-01-30 国立大学法人大阪大学 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591880A (ja) * 1991-02-28 1993-04-16 Nippon Koutai Kenkyusho:Kk ヒトｍｋ遺伝子
EP0569703A2 (en) * 1992-04-24 1993-11-18 American Cyanamid Company Method of treating and preventing viral infections using HBNF and MK protein
WO1994013800A2 (en) * 1992-12-11 1994-06-23 Cancer Research Campaign Technology Limited Mk protein preparation and use in cell culture
WO1999003493A1 (fr) * 1997-07-14 1999-01-28 Meiji Milk Products Co., Ltd. Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
WO1999038971A1 (fr) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Proteine se liant a la midkine
JP2000072799A (ja) * 1998-08-24 2000-03-07 Meiji Milk Prod Co Ltd チロシンに富むレセプター様タンパク質
JP2004012447A (ja) * 2002-06-05 2004-01-15 Takashi Muramatsu リウマチの診断法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591880A (ja) * 1991-02-28 1993-04-16 Nippon Koutai Kenkyusho:Kk ヒトｍｋ遺伝子
EP0569703A2 (en) * 1992-04-24 1993-11-18 American Cyanamid Company Method of treating and preventing viral infections using HBNF and MK protein
WO1994013800A2 (en) * 1992-12-11 1994-06-23 Cancer Research Campaign Technology Limited Mk protein preparation and use in cell culture
WO1999003493A1 (fr) * 1997-07-14 1999-01-28 Meiji Milk Products Co., Ltd. Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
WO1999038971A1 (fr) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Proteine se liant a la midkine
JP2000072799A (ja) * 1998-08-24 2000-03-07 Meiji Milk Prod Co Ltd チロシンに富むレセプター様タンパク質
JP2004012447A (ja) * 2002-06-05 2004-01-15 Takashi Muramatsu リウマチの診断法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MURAMATSU T.: "MIDKINE AND PLEIOTROPHIN: TWO RELATED PROTEINS INVOLVED IN DEVELOPMENT, SURVIVAL, INFLAMMATION AND TUMORIGENESIS", JOURNAL OF BIOCHEMISTRY, vol. 132, no. 3, September 2002 (2002-09-01), pages 359 - 371, XP009009323 *
TAKADA T. ET AL: "MIDKINE A RETINOIC ACID-INDUCIBLE HEPARIN-BINDING CYTOKINE IN INFLAMMATORY RESPONSES: CHEMOTACTIC ACTIVITY TO NEUTROPHILS AND ASSOCIATION WITH INFLAMMATORY SYNOVITIS", JOURNAL OF BIOCHEMISTRY, vol. 122, no. 2, August 1997 (1997-08-01), pages 453 - 458, XP002911186 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055378A1 (ja) * 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
JP5398987B2 (ja) * 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
US8716230B2 (en) 2005-11-14 2014-05-06 Ribomic Inc. Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells
WO2008059877A1 (fr) 2006-11-14 2008-05-22 Ribomic Inc. Aptamère contre la midkine et son utilisation
WO2008059616A1 (fr) 2006-11-14 2008-05-22 Medical Therapies Limited Anticorps reconnaissant le domaine c de la midkine
US8080649B2 (en) 2006-11-14 2011-12-20 Ribomic Inc. Aptamer against midkine and use thereof
JP5190573B2 (ja) * 2006-11-14 2013-04-24 株式会社リボミック ミッドカインに対するアプタマー及びその使用
EP2803674A2 (en) 2006-11-14 2014-11-19 Medical Therapies Limited Antibody recognizing C-domain of midkine
WO2014021339A1 (ja) 2012-07-30 2014-02-06 国立大学法人名古屋大学 ヒトミッドカインに対するモノクローナル抗体
US9840552B2 (en) 2012-07-30 2017-12-12 National University Corporation Nagoya University Monoclonal antibody against human midkine
WO2020022499A1 (ja) * 2018-07-27 2020-01-30 国立大学法人大阪大学 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物

Also Published As

Publication number Publication date
JPWO2004085642A1 (ja) 2006-06-29
JP4646070B2 (ja) 2011-03-09

Similar Documents

Publication Publication Date Title
Humby et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
Greenbaum et al. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
Kissel et al. Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
Bai et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: a systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients
Lee Classification systems for chronic graft-versus-host disease
Krenn et al. Synovitis score: discrimination between chronic low‐grade and high‐grade synovitis
Nerviani et al. A pauci-immune synovial pathotype predicts inadequate response to TNFα-blockade in rheumatoid arthritis patients
Reyes-Castillo et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features
Maksymowych Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy
Dubois et al. A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells
Szodoray et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system
Zendman et al. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis
Pallier et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype
Ishizu et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis
Kirkham et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two‐year prospective study (the DAMAGE study cohort)
Chalan et al. Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients
EP2293209A3 (en) Method and apparatus for detecting and predicting biological anomalies and cerebral disorders
Wilkinson et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies
Parodis et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
WO2003014395A1 (fr) Methode d'examen de l'asthme bronchique
Chong et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients
Hu et al. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD
Okamoto et al. Association of sputum neutrophil extracellular trap subsets with IgA anti–citrullinated protein antibodies in subjects at risk for rheumatoid arthritis
JP2021063826A (ja) 生物学的製剤による関節リウマチの治療効果を予測判定する方法
CN104732116A (zh) 一种基于生物网络的癌症驱动基因的筛选方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005504126

Country of ref document: JP

122 Ep: pct application non-entry in european phase